Cyclacel Pharmaceuticals Earnings Calls

Q4 2024 (Upcoming)
Release date Mar 18, 2025
EPS estimate -$0.290
EPS actual -
Revenue estimate -
Revenue actual -
Expected change +/- 11.89%
Q3 2024 Beat
-$0.180 (66.67%)
Release date Nov 12, 2024
EPS estimate -$0.540
EPS actual -$0.180
EPS Surprise 66.67%
Revenue estimate 10K
Revenue actual 10K
Q2 2024 Beat
-$0.720 (13.25%)
Release date Aug 14, 2024
EPS estimate -$0.83
EPS actual -$0.720
EPS Surprise 13.25%
Revenue estimate 30K
Revenue actual 4K
Revenue Surprise -86.67%
Q1 2024 Beat
-$2.27 (53.96%)
Release date May 14, 2024
EPS estimate -$4.93
EPS actual -$2.27
EPS Surprise 53.96%
Revenue estimate -
Revenue actual 29K

Last 4 Quarters for Cyclacel Pharmaceuticals

Below you can see how CYCC performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.

Q1 2024 Beat
Release date May 14, 2024
Fiscal end date Mar 31, 2024
Price on release $2.84
EPS estimate -$4.93
EPS actual -$2.27
EPS surprise 53.96%
Date Price
May 08, 2024 $2.32
May 09, 2024 $2.31
May 10, 2024 $2.27
May 13, 2024 $2.54
May 14, 2024 $2.84
May 15, 2024 $2.44
May 16, 2024 $2.34
May 17, 2024 $2.29
May 20, 2024 $2.18
4 days before 22.41%
4 days after -23.24%
On release day -14.08%
Change in period -6.03%
Q2 2024 Beat
Release date Aug 14, 2024
Fiscal end date Jun 30, 2024
Price on release $1.45
EPS estimate -$0.83
EPS actual -$0.720
EPS surprise 13.25%
Date Price
Aug 08, 2024 $1.45
Aug 09, 2024 $1.42
Aug 12, 2024 $1.37
Aug 13, 2024 $1.37
Aug 14, 2024 $1.45
Aug 15, 2024 $1.32
Aug 16, 2024 $1.27
Aug 19, 2024 $1.22
Aug 20, 2024 $1.22
4 days before 0%
4 days after -15.86%
On release day -8.97%
Change in period -15.86%
Q3 2024 Beat
Release date Nov 12, 2024
Fiscal end date Sep 30, 2024
Price on release $0.415
EPS estimate -$0.540
EPS actual -$0.180
EPS surprise 66.67%
Date Price
Nov 06, 2024 $0.415
Nov 07, 2024 $0.426
Nov 08, 2024 $0.481
Nov 11, 2024 $0.449
Nov 12, 2024 $0.415
Nov 13, 2024 $0.450
Nov 14, 2024 $0.393
Nov 15, 2024 $0.374
Nov 18, 2024 $0.361
4 days before -0.0241%
4 days after -12.92%
On release day 8.43%
Change in period -12.94%
Q4 2024 (Upcoming)
Release date Mar 18, 2025
Fiscal end date Dec 30, 2024
Price on release -
EPS estimate -$0.290
EPS actual -
Date Price
Mar 10, 2025 $0.308
Mar 11, 2025 $0.312
Mar 12, 2025 $0.302
Mar 13, 2025 $0.304
Mar 14, 2025 $0.297

Cyclacel Pharmaceuticals Earnings History

Earnings Calendar

FAQ

When is the earnings report for CYCC?
Cyclacel Pharmaceuticals (CYCC) has scheduled its earnings report for Mar 18, 2025 before the markets open.

What is the CYCC price-to-earnings (P/E) ratio?
CYCC P/E ratio as of Mar 14, 2025 (TTM) is -0.0557.

What is the CYCC EPS forecast?
The forecasted EPS (Earnings Per Share) for Cyclacel Pharmaceuticals (CYCC) for the first fiscal quarter 2024 is -$0.290.

What are Cyclacel Pharmaceuticals's retained earnings?
On its balance sheet, Cyclacel Pharmaceuticals reported retained earnings of $10.00 thousand for the latest quarter ending Sep 30, 2024.

What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.

Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.

What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
Click to get the best stock tips daily for free!
ABOUT CYCLACEL PHARMACEUTICALS
Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-...
GOLDEN STAR
Ticker Change Signal Date
ALE
$65.32
0.490% Mar 12
AMED
$92.12
0.488% Mar 12
HESM
$40.63
3.59% Mar 11
HDB
$59.97
1.18% Feb 26
ML
$86.18
0.139% Feb 26

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE